Loading…
← CockpitCompetitor Analysis › 3001.T Katakura Industries Co., Ltd.Open in the cockpit ↗

Katakura Industries Co., Ltd.3001.TCompetitor analysis, valuation and peers

Japan · JPY·Health Care›Pharmaceuticals: Major
Momentum leader 97
Mkt cap
$765M
US dollars, full cap
Free float
41%
of shares outstanding
$/day
$1.26M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
+0.5 pp
WACC 5.0%
Hurdle
-0 pp
Req g minus delivered
Next earnings
89 days
15 Feb 2027
Close · JPY¥3,710
1D-2.0%
1W-3.0%
1M+13.6%
3M+26.5%
6M+39.6%
YTD+28.5%
1Y+40.0%
ATR %4.0%
52w lowhigh10.2% off high

What Katakura Industries does

Employees: 900

Katakura Industries at a glance

Size Katakura Industries (3001.T) is a Japan Health Care company (Pharmaceuticals: Major) with a market value of $765M, the 860th largest of 1,370 Japan companies the cockpit tracks. Shares closed at ¥3,710 on 18 Nov 2026.

Performance Over six months the shares gained 39.6%, against -7.5% for the median peer and -1.4% for the Japan market (cap-weighted) — 4th highest of 19 in its peer set.

Growth Revenue fell 1.5% over the last twelve months (peer median +3.5%); the operating margin is 15.5% (peer median 10.4%).

Valuation It trades at 2.4× enterprise value to sales against a peer median of 2.5× (8th cheapest of 18).

Price implies For today's price to make sense, revenue must grow about 0% a year for seven years (Req g). Recent delivered growth is +1%, so the hurdle is -0 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 0.5 points above its cost of capital (5.0% WACC).

Next results Next results expected around 15 Feb 2027 (exchange calendar; dates can move).

Relative performance

10012014016021 May 202621 Aug 202618 Nov 20263001.T 144Peer median 93
Six months, rebased to 100: Katakura Industries against the median of its 20 peers (local-currency closes).

Katakura Industries financials

Reported figures in JPY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue¥40.4B¥40.7B¥39.4B¥40.0B¥34.3B
Revenue growth—+3%-1%+17%—
Gross profit¥15.0B¥14.4B¥14.5B¥15.1B¥12.6B
EBITDA¥9.27B¥8.76B¥6.95B¥6.46B¥4.05B
Net income¥7.34B¥5.76B¥3.52B¥3.04B¥2.82B
Free cash flown/a¥5.66B¥3.65B¥2.50B-¥1.70B
Capital expendituren/a¥2.67B¥2.06B¥1.11B¥1.05B
Total debt¥6.12B¥8.95B¥11.0B¥12.6B¥14.6B

Quarterly statements and history in the cockpit →

Katakura Industries competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%+100%+150%-50%-25%0%+25%LXRX002390002424BLISSGVS0029072171000411ARDX600479IRWDGUDORIC2186SANOFIRIGL6880733001.T6-month return →1-month return →
Up and to the right = strong over both horizons. Katakura Industries is the large dot.

Fundamentals: revenue growth against valuation

-50%0%+50%0×10×20×30×LXRX002390002424BLISSGVS0029072171000411ARDX600479002349IRWDGUD3001.TRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Katakura Industries is the large dot.

Capital: growth delivered against growth the price implies

0%+20%0%20%002390002424BLISSGVS002907600479GUD3007052186SANOFIRIGL6880733001.TGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Katakura Industries is the large dot.

Katakura Industries competitors and peer comparison

How Katakura Industries compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Katakura Industries against its 20 peers (data as of 18 Nov 2026)
Measure3001.TPeer medianRank in peer set
1-month return+13.6%-6.5%2nd highest of 19
6-month return+39.6%-7.5%4th highest of 19
Distance from 52-week high-10.2%-34.0%3rd highest of 19
Revenue growth (TTM)-1.5%+3.5%6th lowest of 19
Operating margin15.5%10.4%8th highest of 19
EV / Sales2.4×2.5×8th cheapest of 18
Growth the price implies (Req g, 7 yrs)0.3%4.0%6th least demanding of 13
Growth delivered (Del g)+0.5%+2.3%6th lowest of 13
Hurdle (Req g minus delivered)-0.2 pp-4.1 pp5th most demanding of 13
ROIC minus cost of capital+0.5 pp+1.9 pp9th lowest of 18
EV / EBITDA10.4×10.0×4th cheapest of 7
Net debt / EBITDA-2.9×-0.5×least indebted of 8

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Katakura Industries 3001.TJapan$765M+40%-2%15%2.4×0.3%+0.5%
Lexicon Pharmaceuticals LXRXUnited States$766M-22%-46%-147%16.7×n/an/a
Guizhou Xinbang Pharmaceutical 002390.SZChina$771M-7%-13%4%0.9×-3.8%-0.8%
Guizhou Bailing Group Pharmaceutical 002424.SZChina$755M-20%-25%2%2.5×13.5%-0.2%
Bliss GVS Pharma BLISSGVS.NSIndia$777M+141%+25%18%6.7×33.9%+10.1%
Chongqing Pharscin Pharmaceutical 002907.SZChina$752M-7%+8%10%5.3×9.4%-1.4%
Sichuan Neautus Traditional Chinese 2206.HKHong Kong$779Mn/a+7%8%n/an/an/a
CARsgen Therapeutics 2171.HKHong Kong$751M-45%+68%-170%28.6×n/an/a
Zhejiang Int'l 000411.SZChina$783M-21%+3%3%0.3×n/an/a
Ardelyx ARDXUnited States$784M-50%+18%-8%1.6×n/an/a
Zhuzhou Qianjin Pharmaceutical 600479.SSChina$746M-3%+4%11%1.4×-2.1%0.0%
Jinghua Pharmaceutical 002349.SZChina$785M-8%+2%20%3.1×-2.5%+2.6%
Bambusa Therapeutics BBTXUnited States$791Mn/an/an/an/an/an/a
Ironwood Pharmaceuticals IRWDUnited States$791M+22%+18%63%2.6×n/an/a
Knight Therapeutics GUD.TOCanada$792M+41%+36%6%1.8×6.6%+17.7%
Hunan Jiudian Pharmaceutical 300705.SZChina$738M-20%-5%13%1.8×-2.0%+26.1%
Oric Pharmaceuticals ORICUnited States$795M-9%n/an/an/an/an/a
Luye Pharma 2186.HKHong Kong$736M-32%+3%18%1.1×-11.8%+1.9%
Sanofi India SANOFI.NSIndia$797M0%-6%26%4.1×16.3%-8.7%
Rigel Pharmaceuticals RIGLUnited States$801M+48%+2%26%2.5×1.5%+22.1%
Bide Pharmatech 688073.SSChina$801M+10%+10%19%3.1×13.9%+27.7%

Questions

Which companies are Katakura Industries's closest peers?
The cockpit's peer set: Lexicon Pharmaceuticals (LXRX), Guizhou Xinbang Pharmaceutical (002390.SZ), Guizhou Bailing Group Pharmaceutical (002424.SZ), Bliss GVS Pharma (BLISSGVS.NS), Chongqing Pharscin Pharmaceutical (002907.SZ), Sichuan Neautus Traditional Chinese (2206.HK), CARsgen Therapeutics (2171.HK), Zhejiang Int'l (000411.SZ).
Is Katakura Industries expensive compared with its peers?
On ev / sales it trades at 2.4× against a peer median of 2.5×, 8th cheapest of 18 in its peer set. For today's price to make sense, revenue must grow about 0% a year for seven years (Req g). Recent delivered growth is +1%, so the hurdle is -0 pp: the price already allows for a slowdown.
How has Katakura Industries stock performed?
Over six months to 18 Nov 2026 the shares returned +39.6% against -7.5% for the median peer; over one year +40.0%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.